Table 9.

Summary of radiolabeled CCK/minigastrin analogues for CCKR-positive tumor imaging over past 3 years.

Composition of Studied Compounds - Metal Radionuclide - BFCA - Linker - Peptide	Results and Findings - Phase of Trials - Cancer Type Studied - Imaging Technique Used - Benefits/Limitations/Conclusion	Reference
- 68Ga, 89Zr - fusarinine C (FSC) - x -MG11	- preclinical in vitro, in vivo - epidermoid - microPET/CT - decreased hydrophilicity, increased metabolic stability and kidney retention for dimer and trimer, and reduced TBR of 89Zr-monomer and dimers	[160]
- 111In - DOTA - x - minigastrins MGS1, MGS2, MGS3, MGS4	- preclinical in vitro, in vivo - epidermoid, pancreatic - nanoSPECT/CT - modified C-terminal of [111In]In-DOTA-MGS4 led to high CCK2R affinity, an improved biodistribution profile and a promising in vivo stability, tumor targeting, and TBR	[161]
- 99mTc - HYNIC, EDDA - x -MGS5, MGS11	- preclinical in vitro, in vivo - epidermoid - gamma counter, autoradiography - [99mTc]Tc-HYNIC-MGS11 with high resistance against enzymatic degradation and useful targeting profile similar to DOTA-analogue; a promising kit development of for CCK2R-imaging and radioguided surgery	[162]
- 111In - DOTA - x - (D-Glu1−6)minigastrin	- clinical, 16 patients - advanced medullary thyroid - SPECT/CT - high uptake in lesions and favorable dosimetry confirmed, but increased calcitonin concentrations in blood; initiation of 177Lu-analogue assessment	[163]